Email this article Advisory Council on combined immunochemotherapy for urothelial cancer
- Issue: Vol 16, No 3 (2020)
- Pages: 209-211
- Section: RESOLUTION
- Published: 30.09.2020
- URL: https://oncourology.abvpress.ru/oncur/article/view/1364
- DOI: https://doi.org/10.17650/1726-9776-2020-16-3-209-211
- ID: 1364
Cite item
Full Text
Abstract
Москва, 7 июля 2020 г.
7 июля 2020 г. состоялось заседание консультационного совета, посвященное новому комбинированному иммунохимиотерапевтическому подходу в 1-й линии терапии пациентов с местнораспространенным или метастатическим уротелиальным раком.
Keywords
References
- NCCN Clinical Practice Guidelines in Oncology, Bladder Cancer, v.4. 2019.
- von der Maase H., Sengelov L., Roberts J.T. et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005;23(21):4602-8. doi: 10.1200/JCO.2005.07.757.
- De Santi M., Bellmunt J., Mead G. et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 2012;30(2):191-9. doi: 10.1200/JCO.2011.37.3571.
- Socinski M.A., Jotte R.M., Cappuzzo F. et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 2018;378:2288-301. doi: 10.1056/NEJMoa1716948.
- Schmid P., Adams S., Rugo H.S. et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 2018;379:2108-21. doi: 10.1056/NEJMoa1809615.
- Burtness B., Harrington K.J., Greil R. et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019;394(10212):1915-28. doi: 10.1016/S0140-6736(19)32591-7.
- Finn R.S., Qin S., Ikeda M. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020;382: 1894-905. doi: 10.1056/NEJMoa1915745.
- Galsky M.D., Arija J.A.A., Bamias A. et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2020;395(10236):1547-57. doi: 10.1016/S0140-6736(20)30230-0.
- Wang Y., Zhou S., Yang F. et al. Treatment related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol 2019. doi: 10.1001/jamaoncol.2019.0393.
Supplementary files
